Infliximab (Pediatric)
A TNF-alpha blocker. It is a monoclonal antibody that reduces inflammation in the gut and is used when other drugs fail.
Dosage by Body Weight
Pediatric dose: 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
- Body Weight
- 20-40 kg
- Dose
- 100 mg to 200 mg
- Frequency
- As per schedule
- Tracking Notes
- Must be screened for Tuberculosis before starting.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| 20-40 kg | 100 mg to 200 mg | As per schedule | Must be screened for Tuberculosis before starting. |
Formulation
Purpose
Treatment of severe Crohn's Disease and Ulcerative Colitis in children (ages 6+).
Generic Name
InfliximabBranded Drug Names
Infliximab (Pediatric) is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.
Alternatives
Safety Advice
Alcohol
CAUTIONInfliximab (Pediatric): Alcohol can increase liver strain, stomach irritation, or immune-related complications. Avoid alcohol unless your specialist allows it.
Pregnancy
CAUTIONInfliximab (Pediatric): Use in pregnancy only under specialist advice because immune, cancer, or transplant treatment requires careful risk assessment.
Breast Feeding
CAUTIONInfliximab (Pediatric): Breastfeeding may not be recommended with some immunosuppressive or chemotherapy medicines. Follow specialist advice.
Driving
CAUTIONInfliximab (Pediatric): May cause dizziness, fatigue, nausea, or weakness. Avoid driving if affected.
Liver
CAUTIONInfliximab (Pediatric): Can affect liver function and usually requires regular blood tests. Use only with specialist monitoring.
Kidney
CAUTIONInfliximab (Pediatric): Kidney function may need close monitoring, particularly with calcineurin inhibitors or high-risk regimens.